Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Treace Medical Concepts ( (TMCI) ) has shared an announcement.
Treace Medical Concepts reported preliminary, unaudited revenue results for the fourth quarter and full year 2024, showing a 10% increase in fourth-quarter revenue and a 12% annual growth. The company added approximately 280 new active surgeons in 2024, expanding its surgeon base by 10%. These results position Treace for continued growth in 2025, supported by new product launches and enhanced market penetration.
More about Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company focusing on the advancement of surgical care for bunion and related midfoot deformities. Its flagship products include the Lapiplasty® and Adductoplasty® systems, which aim to correct bunion deformities and support midfoot correction. The company also offers SpeedPlate™ Rapid Compression Implants for various foot surgical procedures.
YTD Price Performance: -7.24%
Average Trading Volume: 487,073
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $454.8M
For an in-depth examination of TMCI stock, go to TipRanks’ Stock Analysis page.
